SPRB
SPRUCE BIOSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$53.05
−1.50%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$53.04
From 52W high−70.95%
Volume99660.00
Market cap$152.47M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$53.04
From 52W high
−70.95%
Volume
99660.00
Market cap
$152.47M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
P/E (TTM)
—
RSI (14)
44.7
MomentumView details →
1D Return
−1.50%
YTD Return
−40.12%
SummaryUpdated Jun 1, 2026
Spruce Biosciences, Inc. (NASDAQ:SPRB) is a biopharmaceutical company founded in 2014 and headquartered in Daly City, California. The company went public in October 2020 and has undergone a significant strategic transformation. Originally focused on developing treatments for congenital adrenal hyperplasia (CAH), Spruce pivoted in 2024 to acquire and develop Tralesinidase Alfa, an enzyme replacement therapy for a rare pediatric neurodegenerative disease called MPS IIIB (Mucopolysaccharidosis IIIB or Sanfilippo syndrome type B).
Similar companies
Latest newsMore news →
Spruce Biosciences launched MPS3BStudy.com, an online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB), enabling them to learn about and register interest in a related study.25d agoSpruce Biosciences hired Adrian Quartel as chief medical officer.30d agoCure Sanfilippo Foundation and the National MPS Society agreed to make a combined $5.5 million strategic investment in Spruce Biosciences.39d ago